Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry

Blood Cancer Discovery · Published 2026-06-12 · DOI 10.1158/2643-3230.bcd-25-0259

Free full text

Authors (35)

Kylee Maclachlan, Marios Papadimitriou, Patrick Blaney, Linda B. Baughn, Tala Shekarkhand, Alexandra M. Poos, Bachisio Ziccheddu, Hongwei Tang, Huihuang Yan, Benjamin Diamond, Yanming Zhang, Robert Cimera, Ahmet Dogan, Dylan Gagler, Eileen Boyle, Malin Hultcrantz, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Carlyn R. Tan, Elizabeth E. Brown, Lara Winterkorn, Timothy Chu, Zoe Steinsnyder, Zalman Vaksman, Faith E. Davies, Neha Korde, Ola Landgren, Marc S. Raab, Alexander Lesokhin, Nicolas Robine, Niels Weinhold, Saad Z. Usmani, Francesco Maura, Gareth J. Morgan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Maclachlan, K., Papadimitriou, M., Blaney, P., et al. (2026). Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry. Blood Cancer Discovery. https://doi.org/10.1158/2643-3230.bcd-25-0259

Related articles

• Improving Knowledge and Care of Patients with AML: The Need to Get Out of Our Comfort Zone · Blood Cancer Discovery · 2026 · Same journal
• MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1 -Mutant Leukemia · Blood Cancer Discovery · 2026 · Same journal
• LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models · Blood Cancer Discovery · 2026 · Same journal
• Rewiring the Leukemic Genome: 3D Chromatin Architecture in B-cell Acute Lymphoblastic Leukemia · Blood Cancer Discovery · 2026 · Same journal
• The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells · Blood Cancer Discovery · 2026 · Same journal
• Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies · Blood Cancer Discovery · 2026 · Same journal
• Highlighted Research Articles · Blood Cancer Discovery · 2026 · Same journal
• Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma · Blood Cancer Discovery · 2026 · Same journal
• Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial · Blood Cancer Discovery · 2026 · Same journal
• A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma · Blood Cancer Discovery · 2026 · Same journal